Wrapmanager Inc. Trims Holdings in AstraZeneca PLC (NASDAQ:AZN)

Wrapmanager Inc. decreased its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 9.2% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 4,693 shares of the company’s stock after selling 473 shares during the quarter. Wrapmanager Inc.’s holdings in AstraZeneca were worth $366,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. McClarren Financial Advisors Inc. boosted its stake in AstraZeneca by 320.8% in the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after buying an additional 247 shares during the last quarter. GHP Investment Advisors Inc. purchased a new position in AstraZeneca during the second quarter worth approximately $26,000. Capital Performance Advisors LLP acquired a new position in shares of AstraZeneca in the 3rd quarter valued at $28,000. Pathway Financial Advisers LLC purchased a new stake in shares of AstraZeneca during the 1st quarter valued at $29,000. Finally, Hobbs Group Advisors LLC purchased a new position in shares of AstraZeneca in the 2nd quarter worth $35,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Finally, TD Cowen upped their target price on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Stock Performance

AZN opened at $63.80 on Wednesday. The company has a market capitalization of $197.82 billion, a price-to-earnings ratio of 30.53, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The business has a 50 day moving average price of $74.34 and a two-hundred day moving average price of $78.06.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same period last year, the company posted $0.87 earnings per share. The firm’s quarterly revenue was up 18.0% compared to the same quarter last year. Research analysts predict that AstraZeneca PLC will post 4.07 EPS for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.